Sonoma Pharmaceuticals (SNOA) Free Cash Flow (2010 - 2026)
Sonoma Pharmaceuticals' (SNOA) quarterly Free Cash Flow came in at -$548000.0 in Q1 2026, down 285.92% year-on-year from $294757.6 in Q1 2025, and up 32.43% quarter-over-quarter from -$811000.0 in Q4 2025.
Sonoma Pharmaceuticals (SNOA) Free Cash Flow (2010 - 2026) Analysis & Trends
Sonoma Pharmaceuticals' Free Cash Flow history runs 17 years deep, the most recent figure standing at -$548000.0 for Q1 2026.
- On a quarterly basis, Free Cash Flow fell 285.92% year-over-year to -$548000.0 in Q1 2026; TTM through Mar 2026 was -$4.1 million, a 2355.36% decrease from a year earlier, with the FY2026 full-year figure at -$4.1 million, down 2355.36% from the prior year.
- Free Cash Flow climbed to -$548000.0 in Q1 2026 per SNOA's latest filing, from -$811000.0 in the prior quarter.
- Across five years, Free Cash Flow topped out at $563000.0 in Q4 2024 and bottomed at -$2.6 million in Q1 2023.
- The 5-year median for Free Cash Flow is -$811000.0 (2025), against an average of -$857117.6.
- Across the five-year window, Free Cash Flow soared 150.95% in 2024 and tumbled 296.65% in 2025, its largest moves.
- Year by year, Free Cash Flow stood at -$379000.0 in 2022, then tumbled by 191.56% to -$1.1 million in 2023, then surged by 150.95% to $563000.0 in 2024, then slumped by 244.05% to -$811000.0 in 2025, then jumped by 32.43% to -$548000.0 in 2026.
- Per Business Quant, the three latest SNOA Free Cash Flow figures stand at -$548000.0 (Q1 2026), -$811000.0 (Q4 2025), and -$645000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -208.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 291.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -373.37 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 363.70 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 348.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 144.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -38.00 Mn |
| 10 | Sonoma Pharmaceuticals | 179.80 | -2.40 Mn | 2.18 Mn | -548,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -548,000.00 |
| Mar 31, 2026 | -548,000.00 |
| Dec 31, 2025 | -811,000.00 |
| Dec 31, 2025 | -811,000.00 |
| Sep 30, 2025 | -645,000.00 |
| Sep 30, 2025 | -645,000.00 |
| Jun 30, 2025 | -2.12 Mn |
| Jun 30, 2025 | -2.12 Mn |
| Mar 31, 2025 | -142,000.00 |
| Mar 31, 2025 | -142,000.00 |
| Dec 31, 2024 | 563,000.00 |
| Dec 31, 2024 | 563,000.00 |
| Sep 30, 2024 | 328,000.00 |
| Sep 30, 2024 | 328,000.00 |
| Jun 30, 2024 | -917,000.00 |
| Jun 30, 2024 | -917,000.00 |
| Mar 31, 2024 | 170,000.00 |
| Mar 31, 2024 | 170,000.00 |
| Dec 31, 2023 | -1.11 Mn |
| Dec 31, 2023 | -1.11 Mn |